source
- CEPI pledges up to $16.5M to advance Egyptian biotech's Ebola vaccine candidateCEPI has committed up to $16.5 million to help bring Minapharm’s Bundibugyo Ebola vaccine candidate into clinical testing. The funding will support preclinical work and an early-stage human trial…
- FDA greenlights first oral therapy for adult dermatomyositisThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as a treatment for adults with dermatomyositis. Dermatomyositis is a rare autoimmune condition that attacks muscle…